Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12630209 | 0.75 | KDM4E (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2013241 | 0.74 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL17928609 | 0.72 | CYP1A2 (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL14249026 | 0.71 | NCF1 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2013271 | 0.71 | LMNA (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9834398 | 0.70 | MAOA (0.50) | MAOAMAOBLMNAKDM4EHTT | |
| SCHEMBL14314433 | 0.70 | NCF1 (0.35) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2014624 | 0.67 | MAPT (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9098426 | 0.67 | ACHE (0.51) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL13865282 | 0.64 | POLB (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120822-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-01 | — | — | US | disclosed |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG | 2015-03-12 | — | — | US | disclosed |
| US-8927541-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| EP-2513115-B1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2013-10-09 | — | — | EP | disclosed |
| EP-2513115-A1 | TRICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011073378-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | CBR1, CBR3, C1S | GABRA1 2408/4885GABRG2 3098/4885GABRB3 3169/4885 |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | TREH, MRPL21, SPOUT1 | GABRA1 3802/4885GABRG2 4043/4885GABRB3 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.